Form 4: ALUMIS CDO Granted 190,225 Stock Options

ALUMIS Inc.'s Chief Development Officer, Mark Christopher Bradley, was granted 190,225 stock options with an exercise price of $26.31.

Summary

• Chief Development Officer Mark Christopher Bradley of ALUMIS INC. was granted 190,225 stock options.
• The options have an exercise price of $26.31 per share.
• The grant date for these options was January 26, 2026.
• The options expire on January 25, 2036.
• The vesting schedule dictates that 25% of the shares vest on January 26, 2027, with the remainder vesting in equal monthly installments over the subsequent 36 months, contingent on continuous service.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management alignment and long-term incentive. It's a routine compensation event, not directly impacting immediate financial performance, but reflects confidence in future growth.

Positives

• The grant of stock options to a key executive (Chief Development Officer) can align management's interests with shareholders, incentivizing long-term value creation.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary transaction.

Risks

• The value of the options is dependent on ALUMIS INC.'s stock price appreciating above the exercise price of $26.31.
• Vesting is subject to the Reporting Person's Continuous Service, meaning the options could be forfeited if employment ceases before vesting.

Future Outlook

The grant of long-term stock options suggests an expectation of future growth and value creation for ALUMIS INC., as the options' value is tied to the company's stock price performance over the next decade.

Industry Context

Executive equity grants are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key talent, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The grant of 190,225 stock options to a Chief Development Officer is a significant equity award, common for senior executives in growth-oriented biotech or pharmaceutical companies.
• An exercise price of $26.31 suggests this was an 'at-the-money' grant, typical for new option awards, where the exercise price is set at the market price on the grant date.
• A 10-year expiration period (until January 25, 2036) is standard for employee stock options, providing a long-term incentive horizon.
• The 4-year vesting schedule (25% after one year, then monthly over 36 months) is a common industry practice designed to encourage long-term retention and performance.

Stakeholder Impact

• Shareholders: Potential positive impact if the options incentivize the CDO to drive company growth, leading to stock price appreciation. Dilution risk if options are exercised in the future, though this is standard for equity compensation.
• Employees: Standard equity compensation practices can positively influence employee morale and retention, especially for key executives.

Next Steps

• Monitor ALUMIS INC.'s stock performance relative to the $26.31 exercise price.
• Observe future Form 4 filings for any exercise or sale of these options by Mr. Bradley.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a key executive, which is a standard compensation practice and does not provide new information warranting a change in investment recommendation. The grant aligns executive incentives with long-term shareholder value, but does not signal immediate operational or financial changes. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

ALUMIS INC., ALMS, Stock Option, Insider Transaction, Form 4, Executive Compensation, Equity Incentive, Chief Development Officer, Mark Christopher Bradley